RePORT ⟩ RePORTER

Project Details

Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic TrialsPOP: 09/15/2014-09/14/2015

Project Number261201200013I-0-26100008-1

Contact PI/Project LeaderRAO, CHINTHALAPALLY

Awardee Organization

Description

Abstract Text

The contract is to perform molecular analyses on pre- and post-treatment duodenal and colonic polyps as well as histologically normal tissue from FAP/AFAP participants in an existing randomized, placebo-controlled, phase II clinical trial of sulindac and erlotinib or other appropriately selected chemopreventive agents. The ultimate goal shall be to correlate the pathways that contain these markers with mechanisms of colon carcinogenesis and of drug action in inhibiting this process.

Public Health Relevance Statement

Data not available.

NIH Spending Category

CancerColo-Rectal CancerDigestive DiseasesGeneticsPrevention

Project Terms

AddressAftercareCandidate Disease GeneChemopreventionChemopreventive AgentClinical ChemopreventionClinical TrialsColon CarcinomaColonic PolypsContractorContractsDrug effect disorderEnsureErlotinibGene ExpressionGenesGoalsGrowth FactorHeterogeneityHistologicIndividualInflammationMolecularMucous MembraneMutateMutationNormal tissue morphologyParticipantPathway interactionsPatientsPhase II Clinical TrialsPlacebo ControlPolypsPreventionProcessRandomizedResistanceSamplingSourceSulindacTherapeuticTissuescolon carcinogenesisgenetic analysisgenetic pedigreeoverexpression

Details

Contact PI/ Project Leader

Name

RAO, CHINTHALAPALLY

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

City

Country

UNITED STATES

Department Type

Unavailable

Organization Type

Unavailable

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2014

Award Notice Date

Administering Institutes or Centers

National Cancer Institute

CFDA Code

DUNS Number

UEI

Project Start Date

15-September-2014

Project End Date

14-September-2015

Budget Start Date

Budget End Date

Project Funding Information for 2014

Total Funding

$482,037

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2014	National Cancer Institute	$482,037

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL CANCER INSTITUTE	$482,037	Cancer; Colo-Rectal Cancer; Digestive Diseases; Genetics; Prevention

Sub Projects

No Sub Projects information available for 261201200013I-0-26100008-1

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 261201200013I-0-26100008-1

Patents

No Patents information available for 261201200013I-0-26100008-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 261201200013I-0-26100008-1

Clinical Studies

No Clinical Studies information available for 261201200013I-0-26100008-1

News and More

Section Menu